TRPC2

Across TCGA pan-cancer cohorts, TRPC2 RNA is linked to patient survival in 23 of 34 cancer types, making it the most broadly survival-associated TRPC2 data layer.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TRPC2 RNA is associated with better overall survival. In most high-consensus cancer types, elevated TRPC2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and KIRC show a favorable association.

LUAD, KIRC, and KIRP are the cancer types where TRPC2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	All	0.787	0.594	<.001	60	view →
KIRC	DFS	Median	III,IV	0.837	0.649	.003	36	view →
KIRP	DFS	Median	II,III,IV	0.914	0.246	<.001	28	view →
LGG	DFS	Median	All	0.660	0.802	<.001	26	view →
SKCM	OS	Quartile	III,IV	0.748	0.538	.006	26	view →
ACC	OS	Tertile	III,IV	0.582	0.906	.004	25	view →
OV	OS	Median	IV	0.255	0.462	.010	18	view →
CHOL	DFS	Median	All	0.858	0.130	.003	18	view →
GBM	DFS	Quartile	All	0.182	0.296	.009	15	view →
CESC	OS	Tertile	All	0.774	0.474	.009	14	view →
PRAD	DFS	Tertile	All	0.825	0.940	<.001	14	view →
UCEC	OS	Median	All	0.837	0.905	.007	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 23 lineages.

TRPC2–LUAD (OS)

Open the LUAD breakdown →